Flat PV fee possible as EU rewrites earlier ‘disproportionate’ proposals
This article was originally published in Scrip
Drug companies in the EU could be looking at paying the European Medicines Agency a flat fee – presumably annually – to cover the agency’s responsibilities under the new EU pharmacovigilance legislation.
You may also be interested in...
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.